Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ching-Lin Hsieh

Showing results (241-250 of 258) with videos related to

Pageof 26
Sort By:
Biorxiv : the Preprint Server for Biology|June 25, 2020
Structure-based Design of Prefusion-stabilized SARS-CoV-2 SpikesChing-Lin Hsieh, Jory A Goldsmith, Jeffrey M Schaub, et al.
Cell Reports|September 30, 2021
Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognitionKevin J Kramer, Nicole V Johnson, Andrea R Shiakolas, et al.
Science (New York, N.Y.)|July 25, 2020
Structure-based design of prefusion-stabilized SARS-CoV-2 spikesChing-Lin Hsieh, Jory A Goldsmith, Jeffrey M Schaub, et al.
Elife|March 21, 2023
Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronavirusesRui P Silva, Yimin Huang, Annalee W Nguyen, et al.
Communications Biology|December 11, 2023
SARS-COV-2 Omicron variants conformationally escape a rare quaternary antibody binding modeJule Goike, Ching-Lin Hsieh, Andrew P Horton, et al.
Science (New York, N.Y.)|June 17, 2020
Broad neutralization of SARS-related viruses by human monoclonal antibodiesAnna Z Wec, Daniel Wrapp, Andrew S Herbert, et al.
Vaccine|May 16, 2022
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in VietnamAnh Duc Dang, Thiem Dinh Vu, Ha Hai Vu, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike proteinAnna Z Wec, Daniel Wrapp, Andrew S Herbert, et al.
Medrxiv : the Preprint Server for Health Sciences|September 28, 2021
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 TrialPunnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
Eclinicalmedicine|March 14, 2022
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trialPunnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
Pageof 26

Showing results (241-250 of 258) with videos related to

Sort By:
Pageof 26
Biorxiv : the Preprint Server for Biology|June 25, 2020
Structure-based Design of Prefusion-stabilized SARS-CoV-2 SpikesChing-Lin Hsieh, Jory A Goldsmith, Jeffrey M Schaub, et al.
Cell Reports|September 30, 2021
Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognitionKevin J Kramer, Nicole V Johnson, Andrea R Shiakolas, et al.
Science (New York, N.Y.)|July 25, 2020
Structure-based design of prefusion-stabilized SARS-CoV-2 spikesChing-Lin Hsieh, Jory A Goldsmith, Jeffrey M Schaub, et al.
Elife|March 21, 2023
Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronavirusesRui P Silva, Yimin Huang, Annalee W Nguyen, et al.
Communications Biology|December 11, 2023
SARS-COV-2 Omicron variants conformationally escape a rare quaternary antibody binding modeJule Goike, Ching-Lin Hsieh, Andrew P Horton, et al.
Science (New York, N.Y.)|June 17, 2020
Broad neutralization of SARS-related viruses by human monoclonal antibodiesAnna Z Wec, Daniel Wrapp, Andrew S Herbert, et al.
Vaccine|May 16, 2022
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in VietnamAnh Duc Dang, Thiem Dinh Vu, Ha Hai Vu, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2020
Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike proteinAnna Z Wec, Daniel Wrapp, Andrew S Herbert, et al.
Medrxiv : the Preprint Server for Health Sciences|September 28, 2021
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 TrialPunnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
Eclinicalmedicine|March 14, 2022
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trialPunnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
Pageof 26